CN116709924A - 用于治疗移植物抗宿主病的设计的细菌组合物 - Google Patents
用于治疗移植物抗宿主病的设计的细菌组合物 Download PDFInfo
- Publication number
- CN116709924A CN116709924A CN202180090783.5A CN202180090783A CN116709924A CN 116709924 A CN116709924 A CN 116709924A CN 202180090783 A CN202180090783 A CN 202180090783A CN 116709924 A CN116709924 A CN 116709924A
- Authority
- CN
- China
- Prior art keywords
- composition
- subject
- bacteria
- species
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Agronomy & Crop Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118639P | 2020-11-25 | 2020-11-25 | |
| US63/118,639 | 2020-11-25 | ||
| PCT/US2021/060878 WO2022115646A1 (en) | 2020-11-25 | 2021-11-24 | Designed bacterial compositions for treating graft-versus-host-disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116709924A true CN116709924A (zh) | 2023-09-05 |
Family
ID=81756137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180090783.5A Pending CN116709924A (zh) | 2020-11-25 | 2021-11-24 | 用于治疗移植物抗宿主病的设计的细菌组合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240000859A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4250932A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023550652A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230124601A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116709924A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021388169A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3199153A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006146A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022115646A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117907608A (zh) * | 2024-03-19 | 2024-04-19 | 苏州和锐生物科技有限公司 | 一种Claudin2蛋白的检测方法及其相关产品和应用 |
| CN118987051A (zh) * | 2024-09-13 | 2024-11-22 | 南方医科大学南方医院 | 粪副拟杆菌在制备治疗移植物抗宿主病药物中的应用 |
| CN120305292A (zh) * | 2024-09-13 | 2025-07-15 | 南方医科大学南方医院 | 粪副拟杆菌在制备分离移植物抗白血病效应与移植物抗宿主病药物中的应用 |
| CN120700173A (zh) * | 2025-09-01 | 2025-09-26 | 华中科技大学同济医学院附属协和医院 | 甲状腺相关眼病的微生物标志物、产品及其应用 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4341382A4 (en) * | 2021-05-10 | 2025-04-30 | Microba Ip Pty Ltd | COMPOSITIONS AND METHODS FOR TREATING DISEASES |
| CN114788837B (zh) * | 2022-06-07 | 2023-09-05 | 青岛东海药业有限公司 | 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用 |
| EP4687930A2 (en) * | 2023-01-30 | 2026-02-11 | Seres Therapeutics, Inc. | Use of designed bacterial compositions for infection treatment |
| GB2627012A (en) * | 2023-02-13 | 2024-08-14 | Acad Medisch Ct | Predictive biomarker of neonatal E.coli mediated sepsis |
| AU2024327567A1 (en) * | 2023-08-22 | 2026-01-08 | Danisco Usa Inc. | Methods and compositions for immune system regulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015006491A (es) * | 2012-11-23 | 2015-12-03 | Seres Health Inc | Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas. |
| EP2951283A4 (en) * | 2013-02-04 | 2017-01-25 | Seres Therapeutics, Inc. | Compositions and methods |
| MX369877B (es) * | 2013-02-04 | 2019-11-25 | Seres Therapeutics Inc | Composiciones y metodos. |
| JP2016519664A (ja) * | 2013-03-15 | 2016-07-07 | セレス セラピューティクス インコーポレイテッド | ネットワークを基にした微生物組成物及び方法 |
| MX367109B (es) * | 2013-11-25 | 2019-08-05 | Seres Therapeutics Inc | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| US20190247447A1 (en) * | 2015-11-24 | 2019-08-15 | Seres Therapeutics, Inc. | Designed bacterial compositions |
| EP3379935A4 (en) * | 2015-11-25 | 2019-08-28 | Memorial Sloan-Kettering Cancer Center | METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN |
| AU2017234120B2 (en) * | 2016-03-14 | 2024-06-20 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| KR102658297B1 (ko) * | 2016-06-14 | 2024-04-18 | 베단타 바이오사이언시즈, 인크. | 클로스트리디움 디피실레 감염의 치료 |
| KR20200038506A (ko) * | 2017-08-07 | 2020-04-13 | 핀치 테라퓨틱스, 인코포레이티드 | 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법 |
| JP2020530493A (ja) * | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド. | 腸内の抗生物質耐性菌を除菌するための組成物及び方法 |
| BR112020002992A2 (pt) * | 2017-08-14 | 2020-08-18 | Seres Therapeutics, Inc. | composições e métodos para tratamento de doença colestática |
| JP2021512638A (ja) * | 2018-02-09 | 2021-05-20 | 学校法人慶應義塾 | Cd8+t細胞の誘導のための組成物および方法 |
-
2021
- 2021-11-24 AU AU2021388169A patent/AU2021388169A1/en active Pending
- 2021-11-24 EP EP21899146.1A patent/EP4250932A4/en active Pending
- 2021-11-24 JP JP2023531555A patent/JP2023550652A/ja active Pending
- 2021-11-24 CN CN202180090783.5A patent/CN116709924A/zh active Pending
- 2021-11-24 MX MX2023006146A patent/MX2023006146A/es unknown
- 2021-11-24 WO PCT/US2021/060878 patent/WO2022115646A1/en not_active Ceased
- 2021-11-24 CA CA3199153A patent/CA3199153A1/en active Pending
- 2021-11-24 US US18/254,449 patent/US20240000859A1/en active Pending
- 2021-11-24 KR KR1020237021388A patent/KR20230124601A/ko active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117907608A (zh) * | 2024-03-19 | 2024-04-19 | 苏州和锐生物科技有限公司 | 一种Claudin2蛋白的检测方法及其相关产品和应用 |
| CN117907608B (zh) * | 2024-03-19 | 2024-05-24 | 苏州和锐生物科技有限公司 | 一种Claudin2蛋白的检测方法及其相关产品和应用 |
| CN118987051A (zh) * | 2024-09-13 | 2024-11-22 | 南方医科大学南方医院 | 粪副拟杆菌在制备治疗移植物抗宿主病药物中的应用 |
| CN120305292A (zh) * | 2024-09-13 | 2025-07-15 | 南方医科大学南方医院 | 粪副拟杆菌在制备分离移植物抗白血病效应与移植物抗宿主病药物中的应用 |
| CN120700173A (zh) * | 2025-09-01 | 2025-09-26 | 华中科技大学同济医学院附属协和医院 | 甲状腺相关眼病的微生物标志物、产品及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4250932A4 (en) | 2025-07-30 |
| WO2022115646A1 (en) | 2022-06-02 |
| JP2023550652A (ja) | 2023-12-04 |
| AU2021388169A9 (en) | 2024-09-26 |
| EP4250932A1 (en) | 2023-10-04 |
| MX2023006146A (es) | 2023-07-31 |
| KR20230124601A (ko) | 2023-08-25 |
| US20240000859A1 (en) | 2024-01-04 |
| CA3199153A1 (en) | 2022-06-02 |
| AU2021388169A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7165218B2 (ja) | 制御性t細胞の増殖または集積を誘導するヒト由来細菌 | |
| US20240000859A1 (en) | Designed bacterial compositions for treating graft-versus-host-disease | |
| Possemiers et al. | A dried yeast fermentate selectively modulates both the luminal and mucosal gut microbiota and protects against inflammation, as studied in an integrated in vitro approach | |
| CN112512342A (zh) | 设计的细菌组合物及其用途 | |
| EP4076482B1 (en) | Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer | |
| WO2016086209A1 (en) | Probiotic and prebiotic compositions, and methods of use thereof for treatment of gastrointestinal disorders | |
| WO2021195577A2 (en) | Compositions for modulating gut microflora populations, enhancing drug potency and treating viral infections, and methods for making and using same | |
| US20230125810A1 (en) | Designed bacterial compositions and uses thereof | |
| KR20200138333A (ko) | 염증성 장 질환을 치료하는 조성물 및 방법 | |
| JPWO2008023663A1 (ja) | 抗アレルギー作用を有する菌株並びにその菌体を含有する飲料、食品及び抗アレルギー剤 | |
| JP2024518084A (ja) | 疾患を治療するための組成物及び方法 | |
| US20200197513A1 (en) | Nutraceutical blends | |
| WO2021022070A2 (en) | Prebiotic-induced anti-tumor immunity | |
| Luongo et al. | Modulation of the cytokine profile in Caco-2 cells by faecal lactobacilli and bifidobacteria from individuals with distinct dietary habits | |
| US20240066072A1 (en) | Clostrodioides difficile treatment | |
| CN121057584A (zh) | 设计的细菌组合物用于感染治疗的用途 | |
| WO2011027875A1 (ja) | 腸管バリア機能改善剤 | |
| Aminzade et al. | Role in Prediction as Tumor Markers, Diagnosis, and Response to Treatment | |
| KR20260058742A (ko) | 비피도박테리움 롱검 균주 및 이의 용도 | |
| WO2021195636A1 (en) | Microbiome-based therapeutics | |
| HK1261280B (en) | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells | |
| HK1261280A1 (en) | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells | |
| Cianflone et al. | Lactobacillus paracasei F19 Modulates the Inflammatory Response in an Ex Vivo/In Vitro Model of Biopsies Samples From Diarrhea-predominat IBS Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |